Third Harmonic Bio, Inc. (THRD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
300 Technology Square
Cambridge, MA 02139
United States of America (the)
Phone
617-915-6680
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
September 14, 2022
| Name | Title | Pay | Year Born |
| Natalie C. Holles | Chief Executive Officer & Director | 930,248 | 1973 |
| Julie Person | Chief Administrative Officer | 574,000 | 1974 |
| Edward R. Conner | Chief Medical Officer | 672,000 | 1973 |
| Christopher Murphy | Chief Financial & Business Officer | 673,029 | 1984 |
| Christopher J. Dinsmore | Chief Scientific Officer | 0 | 1967 |
| Steven Sweeney | Senior Vice President of Development Operations | 0 | N/A |
| Jennifer Dittman | Chief Operating Officer | 0 | 1982 |
| Dennis Dean | Chief Non-Clinical Development Officer | 0 | 1962 |
| Ommer Chohan | Treasurer & Secretary | 0 | N/A |
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.